High‐Specificity In Vivo Tumor Imaging Using Bioorthogonal NIR‐IIb Nanoparticles
Source abstract
Abstract
Abstract Lanthanide‐based NIR‐IIb nanoprobes are ideal for in vivo imaging. However, existing NIR‐IIb nanoprobes often suffer from low tumor‐targeting specificity, limiting their widespread use. Here the application of bioorthogonal nanoprobes with high tumor‐targeting specificity for in vivo NIR‐IIb luminescence imaging and magnetic resonance imaging (MRI) is reported. These dual‐modality nanoprobes can enhance NIR‐IIb emission by 20‐fold and MRI signal by twofold, compared with non‐bioorthogonal nanoprobes in murine subcutaneous tumors. Moreover, these bioorthogonal probes enable orthotopic brain tumor imaging. Implementation of bio‐orthogonal chemistry significantly reduces the nanoprobe dose and hence cytotoxicity, providing a paradigm for real‐time in vivo visualization of tumors.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry and The N.1 Institute for Health National University of Singapore Singapore 117543 Singapore
Paul C. Lauterbur Research Center for Biomedical Imaging Key Laboratory for Magnetic Resonance and Multimodality Imaging of Guangdong Province Shenzhen Key Laboratory of Ultrasound Imaging and Therapy CAS key laboratory of health informatics Institute of Biomedical and Health Engineering Shenzhen Institute of Advanced Technology Chinese Academy of Sciences Shenzhen 518055 P. R. China
Funding
National Natural Science Foundation of China · Agency for Science, Technology and Research · Key Laboratory for Magnetic Resonance and Multimodality Imaging of Guangdong Province
References (58)
Show source-provided references
1. 10.1038/s41467-017-00917-610.1038/s41467-017-00917-6 ↗
2. 10.1039/C8CS00234G10.1039/C8CS00234G ↗
3. 10.1073/pnas.180615311510.1073/pnas.1806153115 ↗
4. 10.1002/anie.20150747310.1002/anie.201507473 ↗
5. 10.1002/adfm.20180341710.1002/adfm.201803417 ↗
6. 10.1002/adma.20190032110.1002/adma.201900321 ↗
7. 10.1038/s41467-020-15095-110.1038/s41467-020-15095-1 ↗
8. 10.1016/j.trechm.2019.03.00210.1016/j.trechm.2019.03.002 ↗
9. 10.1002/anie.20200998610.1002/anie.202009986 ↗
10. 10.1002/adma.20180816610.1002/adma.201808166 ↗
11. 10.1002/anie.20200764910.1002/anie.202007649 ↗
12. 10.1021/acsnano.0c0004310.1021/acsnano.0c00043 ↗
13. 10.1002/anie.20201190310.1002/anie.202011903 ↗
14. 10.1021/acs.nanolett.9b0036410.1021/acs.nanolett.9b00364 ↗
15. 10.1021/acsnano.8b0753610.1021/acsnano.8b07536 ↗
16. 10.1007/s12274-020-2721-010.1007/s12274-020-2721-0 ↗
17. 10.1021/acs.chemrev.6b0052510.1021/acs.chemrev.6b00525 ↗
18. 10.1038/s41467-020-17772-710.1038/s41467-020-17772-7 ↗
19. 10.1038/nm.293310.1038/nm.2933 ↗
20. 10.1038/ncomms793810.1038/ncomms7938 ↗
21. 10.1021/ja410028q10.1021/ja410028q ↗
22. 10.1002/anie.20130884310.1002/anie.201308843 ↗
23. 10.1002/anie.20181287810.1002/anie.201812878 ↗
24. 10.1002/anie.20171252810.1002/anie.201712528 ↗
25. 10.1038/nmat314910.1038/nmat3149 ↗
26. 10.1038/s41551-016-001010.1038/s41551-016-0010 ↗
27. 10.1002/anie.20190353610.1002/anie.201903536 ↗
28. 10.1039/C4CS00171K10.1039/C4CS00171K ↗
29. 10.1021/acsnano.8b0543110.1021/acsnano.8b05431 ↗
30. 10.1016/j.biomaterials.2018.04.03710.1016/j.biomaterials.2018.04.037 ↗
31. 10.1038/s41467-018-05113-810.1038/s41467-018-05113-8 ↗
32. 10.1038/s41587-019-0262-410.1038/s41587-019-0262-4 ↗
33. 10.1038/s41565-018-0221-010.1038/s41565-018-0221-0 ↗
34. 10.1002/adma.20190240910.1002/adma.201902409 ↗
35. 10.1073/pnas.050427410210.1073/pnas.0504274102 ↗
36. 10.1002/adfm.20190790610.1002/adfm.201907906 ↗
37. 10.1016/j.jconrel.2011.06.00110.1016/j.jconrel.2011.06.001 ↗
38. Park J. W. · Clin. Cancer. Res. · 2002 · 8 · 1172
39. 10.1016/j.jconrel.2012.04.01410.1016/j.jconrel.2012.04.014 ↗
40. 10.1021/ar200148z10.1021/ar200148z ↗
41. 10.1021/jacs.9b0914910.1021/jacs.9b09149 ↗
42. 10.1021/acs.molpharmaceut.6b0108310.1021/acs.molpharmaceut.6b01083 ↗
43. 10.1038/nnano.2010.14810.1038/nnano.2010.148 ↗
44. 10.1002/anie.20120670310.1002/anie.201206703 ↗
45. 10.1002/anie.20180544610.1002/anie.201805446 ↗
46. 10.1002/anie.20201154410.1002/anie.202011544 ↗
47. 10.1002/anie.20110438910.1002/anie.201104389 ↗
48. 10.1038/nchem.192010.1038/nchem.1920 ↗
49. 10.1038/s41568-019-0205-x10.1038/s41568-019-0205-x ↗
50. 10.1016/j.jconrel.2017.12.01510.1016/j.jconrel.2017.12.015 ↗
51. 10.2165/00003088-200746070-0000210.2165/00003088-200746070-00002 ↗
52. 10.1038/nnano.2010.20310.1038/nnano.2010.203 ↗
53. 10.1002/anie.20120319010.1002/anie.201203190 ↗
54. 10.1038/s41467-019-09342-310.1038/s41467-019-09342-3 ↗
55. 10.1186/1532-429X-14-1810.1186/1532-429X-14-18 ↗
56. 10.1002/anie.20210088510.1002/anie.202100885 ↗
57. 10.1002/adma.20190185110.1002/adma.201901851 ↗
58. 10.1016/S0735-1097(02)01777-110.1016/S0735-1097(02)01777-1 ↗